Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

Trial Profile

Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2013

At a glance

  • Drugs Rifaximin (Primary) ; Lactulose
  • Indications Bacterial infections; Hepatic encephalopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2013 Results published in the Annals of Internal Medicine.
    • 31 Jul 2013 New trial record
    • 23 Jul 2013 Results published in the American Journal of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top